Investment Thesis
LabCorp is a financially stable, revenue-growing ($3.5B, +7.2% YoY) medical lab services company with adequate liquidity and debt service capacity, but returns to shareholders are severely constrained by poor capital efficiency (ROE 3.2%) and minimal free cash flow generation (2.0% margin). The $5.8B debt burden is the primary structural headwind limiting profitability conversion.
Strengths
- Solid revenue growth of 7.2% YoY in stable medical services sector
- Strong liquidity position with 1.73x current ratio and 1.54x quick ratio
- Adequate interest coverage of 6.9x indicates comfortable debt servicing capacity
- Positive operating cash flow generation of $191.5M demonstrates underlying business health
Risks
- Critically low ROE of 3.2% and ROA of 1.5% indicating poor returns on shareholder capital
- Weak free cash flow margin of 2.0% limits financial flexibility and reinvestment capacity
- High debt burden of $5.8B relative to $8.7B equity creates significant interest expense drag
- Net margin (7.9%) substantially compressed versus operating margin (10.8%), showing debt service strain
- 71 Form 4 filings in 90 days warrants monitoring for insider sentiment
Key Metrics to Watch
- Free cash flow margin expansion above 2.0%
- Return on Equity improvement trajectory from current 3.2%
- Debt-to-equity ratio reduction through deleveraging
- Operating margin sustainability amid competitive pressures
Financial Metrics
Revenue
3.5B
Net Income
277.8M
EPS (Diluted)
$3.35
Free Cash Flow
70.5M
Total Assets
19.1B
Cash
981.1M
Profitability Ratios
Gross Margin
28.7%
Operating Margin
10.8%
Net Margin
7.9%
ROE
3.2%
ROA
1.5%
FCF Margin
2.0%
Balance Sheet & Liquidity
Current Ratio
1.73x
Quick Ratio
1.54x
Debt/Equity
0.67x
Debt/Assets
54.2%
Interest Coverage
6.91x
Long-term Debt
5.8B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T18:08:21.760180 |
Data as of: 2026-03-31 |
Powered by Claude AI